{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:39:43Z","timestamp":1785425983664,"version":"3.56.0"},"reference-count":37,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"5","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: Diabetic kidney disease (DKD) and diabetic retinopathy (DR) are the most frequent microvascular complications of diabetes mellitus. Although microalbuminuria is a conventional early marker of DKD, its limited sensitivity and the growing recognition of nonalbuminuric DKD highlight the need for more sensitive early detection tools. Urinary biomarkers such as type IV collagen, transferrin, and liver-type fatty acid-binding protein (L-FABP) may capture early glomerular or tubular injury before the onset of overt albuminuria. This pilot study evaluated the diagnostic performance of these biomarkers in adults with type 2 diabetes mellitus (T2DM) and explored their associations with DR.Methods: A cross-sectional per-protocol study included 80 T2DM patients and 10 healthy controls. Diabetic participants were categorised as normoalbuminuric (&amp;lt;30 mg\/day) or microalbuminuric (30-300 mg\/day). First-morning urine samples were used for final analyses. Urinary type IV collagen, transferrin, and L-FABP were quantified using ELISA and expressed in ng\/mL. Group comparisons used t-tests or ANOVA for normally distributed variables, and Mann-Whitney U or Kruskal-Wallis tests for non-normally distributed data. Correlations were assessed using Pearson or Spearman coefficients. Diagnostic performance was analyzed using ROC curves.Results: The cohort (55% male; mean age 59.85\u00b1 8.87 years) had similar BMI, smoking status, and eGFR across groups. Biomarker levels differed significantly among microalbuminuric, normoalbuminuric, and control groups (p&amp;lt;0.001): type IV collagen (0.97 vs. 0.55 vs. 0.48), transferrin (45.51 vs. 14.83 vs. 6.57), and L-FABP (480.15 vs. 228.08 vs. 89.91). Type IV collagen demonstrated the best diagnostic ability for early DKD (AUC 90.4%). DR was present in 24 patients (30%), and transferrin levels were significantly higher in those with DR (81.38 vs. 38.12 ng\/mL; p=0.03).Conclusions: Urinary type IV collagen, transferrin, and L-FABP show promise for early DKD detection, while transferrin additionally correlates with DR. Larger studies are needed to confirm these findings.<\/jats:p>","DOI":"10.5937\/jomb0-61991","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T09:00:28Z","timestamp":1765789228000},"page":"1035-1043","source":"Crossref","is-referenced-by-count":0,"title":["Urinary biomarkers in the early diagnosis of diabetic kidney disease and diabetic retinopathy: A pilot study"],"prefix":"10.5937","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-1714","authenticated-orcid":false,"given":"Brankica","family":"Terzi\u0107","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8591","authenticated-orcid":false,"given":"Zoran","family":"Radoji\u010di\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-6898","authenticated-orcid":false,"given":"Predrag","family":"\u0110uri\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Puali\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6730-9630","authenticated-orcid":false,"given":"Mirko","family":"Resan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6499-1956","authenticated-orcid":false,"given":"Mirjana","family":"Miju\u0161kovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04dt6a039","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","unstructured":"International Diabetes Federation (IDF). IDF Diabetes Atlas 11th edition. idf.org 2025;"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Fouda AY, Xu Z, Suwanpradid J, Rojas M, Shosha E, Lemtalsi T, et al. Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair. Cell Death Dis 2022, 13: 745. doi: 10.1038\/s41419-022-05196-8;","DOI":"10.1038\/s41419-022-05196-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Dash S, Chougule A, Mohanty S. Correlation of Albuminuria and Diabetic Retinopathy in Type-II Diabetes Mellitus Patients. Cureus 2022; 14(2): e21927. doi: 10.7759\/cureus.21927;","DOI":"10.7759\/cureus.21927"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Zhen LT, Yih-Chung T, Marco YM Li Chee, Tyler HR, Ning C, Mukharram MB, Xing YW, et al. Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis. Ophthalmology 2021, 128(11): 1580-91. doi: 10.1016\/j.ophtha.2021.04.027;","DOI":"10.1016\/j.ophtha.2021.04.027"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wong CW, Wong TY, Cheng CY, Sabanayagam C. Kidney and eye diseases: common risk factors, etiological mechanisms, and pathways. Kidney Int 2014, 85: 1290-302. doi: 10.1038\/ki.2013.491;","DOI":"10.1038\/ki.2013.491"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Wilkinson-Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: roles of angiotensin II and aldosterone. Peptides 2012, 36: 142-50. doi: 10.1016\/j.peptides.2012.04.008;","DOI":"10.1016\/j.peptides.2012.04.008"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024; 105(Suppl 4S): S117-S314;","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gupta S, Dominguez M, Golestaneh L. Diabetic Kidney Disease: An Update. Med Clin North Am 2023; 107(4): 689-705. doi: 10.1016\/j.mcna.2023.03.004;","DOI":"10.1016\/j.mcna.2023.03.004"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"AS L, Coresh J, Balk E, Al E. National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139(2): 137-47;","DOI":"10.7326\/0003-4819-139-2-200307150-00013"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liu JF, Qian XP, Wang TX, X L, Liu WG, Wang LJ, Zhang HF, Han L, Li GY, Yu XJ. Complement pathway: Risk molecular pattern. J Med Biochem 2025; 44 (4): 801-7. doi: 10.5937\/jomb0-56221;","DOI":"10.5937\/jomb0-56221"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Gaydarski L, Petrova K, Angushev I, Stanchev S, Iliev A, Stamenov N, Kirkov V, Landzhov B. Exploring the Molecular Modalities in the Pathogenesis of Diabetic Kidney Disease with a Focus on the Potential Therapeutic Implications. Biomedicines 2025, 13(1): 50. doi: 10.3390\/biomedicines13010050;","DOI":"10.3390\/biomedicines13010050"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"McGill JB, Haller H, Roy-Chaudhury P, Cherrington A, Wada T, Wanner C, Ji L, Rossing P. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. BMJ Open Diabetes Res Care 2022, 10(4): e002806. doi: 10.1136\/bmjdrc-2022-002806;","DOI":"10.1136\/bmjdrc-2022-002806"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Uchenna AN, Jeanne AD, Kenneth KC, Zeng B, Arzumanyan H, Lo JC, Zheng S. Prevalence of Albuminuria Among Adults With Diabetes and Preserved Estimated Glomerular Filtration Rate by Race and Ethnicity. Diabetes Care 2023, 46(3): e78-e80. doi: 10.2337\/dc22-1871;","DOI":"10.2337\/dc22-1871"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Scilletta S, Di Marco M, Miano N, Filippello A, Di Mauro S, Scamporrino A, Musmeci M, Coppolino G, Di Giacomo Barbagallo F, Bosco G, Scicali R, Piro S, Purrello F, Di Pino A. Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. Biomolecules 2023, 13(5): 752. doi: 10.3390\/biom13050752;","DOI":"10.3390\/biom13050752"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Zhang C, Liu T, Wang X, Yang J, Qin D, Liang Y, Wang X. Urine biomarkers in type 2 diabetes mellitus with or without microvascular complications. Nutr Diabetes 2024, 14(1): 51. doi: 10.1038\/s41387-024-00310-5;","DOI":"10.1038\/s41387-024-00310-5"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Swaminathan SM, Rao IR, Shenoy SV, Prabhu AR, Mohan PB, Rangaswamy D, Bhojaraja MV, Nagri SK, Nagaraju SR. Novel biomarkers for prognosticating diabetic kidney disease progression. Int Urol Nephrol 2023, 55(4): 913-28. doi: 10.1007\/s11255-022-03354-7;","DOI":"10.1007\/s11255-022-03354-7"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Mahendran KB, Bhaskar MV, Santha K, Inmozhi R, Perumal KK. Plasma and Urinary Type IV Collagen Levels for Early Detection of Nephropathy in Type 2 Diabetes Mellitus Patients. Int J Health Sci (Qassim) 2016, 10(4): 492-8. PMID: 27833513 PMCID: PMC50853;","DOI":"10.5455\/ijmsph.2015.09042015292"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Uwaezuoke SN. The role of novel biomarkers in predicting diabetic nephropathy: a review. Int J Nephrol Renovascular Dis 2017, 10: 221-31. doi: 10.2147\/IJNRD.S143186;","DOI":"10.2147\/IJNRD.S143186"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Claudia G, Sara N de OC, Sabrina RG, Jackson de SM. Urinary Transferrin as a Marker of Renal Injury in Diabetic Individuals: An Integrative Review. J Adv Med Med Res 2024, 36(6): 141-52. doi: 10.9734\/jammr\/2024\/v36i65459;","DOI":"10.9734\/jammr\/2024\/v36i65459"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Li B, Wang J, Ye W. A meta-analysis of urinary transferrin for early diagnosis of diabetic nephropathy. Lab Med 2024, 55(4): 413-9. doi: 10.1093\/labmed\/lmad115;","DOI":"10.1093\/labmed\/lmad115"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"A P C VK, Kalra P. Urinary transferrin as an early marker of renal damage in type II diabetes mellitus: a case-control study. Int J Clin Biochem Res 2021, 8(1): 33-9. Available from: https:\/\/doi.org\/10.18231\/j.ijcbr.2021.008;","DOI":"10.18231\/j.ijcbr.2021.008"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Tanaka T, Doi K, Maeda-Mamiya R, Negishi K, Portilla D, Sugaya T, Fujita T, Noiri E. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am J Pathol 2009, 174(4): 1203-11. doi: 10.2353\/ajpath.2009.080511;","DOI":"10.2353\/ajpath.2009.080511"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011, 34(3): 691-6. doi: 10.2337\/dc10-1392;","DOI":"10.2337\/dc10-1392"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zhang L, Xue S, Wu M, Dong D. Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: a meta-analysis. Front Med (Lausanne) 2022, 9: 914587. doi: 10.3389\/fmed.2022.914587;","DOI":"10.3389\/fmed.2022.914587"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Terzic B, Stanojevic I, Radojicic Z, Resan M, Petrovic D, Maksic Dj, et al. Urinary transferrin as an early biomarker of diabetic nephropathy. Vojnosanit Pregl 2019, 76(6): 616-9. doi: 10.2298\/VSP170808138T;","DOI":"10.2298\/VSP170808138T"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Chawla A, Chawla R, Jaggi S. Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab 2016, 20(4): 546-51. doi: 10.4103\/2230-8210.183480;","DOI":"10.4103\/2230-8210.183480"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rico-Fontalvo J, Aroca-Martinez G, Daza-Arnedo R, Cabrales J, Rodr\u00edguez-Yanez T, Cardona-Blanco M, et al. Novel biomarkers of diabetic kidney disease. Biomolecules 2023, 13(4): 633. doi: 10.3390\/biom13040633;","DOI":"10.3390\/biom13040633"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Diabetes and renal complications: an overview on pathophysiology, biomarkers and therapeutic interventions. Biomedicines 2024, 12(5): 1098. doi: 10.3390\/biomedicines12051098;","DOI":"10.3390\/biomedicines12051098"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Chen C, Wang C, Hu C, Han Y, Zhao L, Zhu X, Xiao L, Sun L. Normoalbuminuric diabetic kidney disease. Front Med 2017, 11(3): 310-8. doi: 10.1007\/s11684-017-0542-7;","DOI":"10.1007\/s11684-017-0542-7"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yamanouchi M, Furuichi K, Hoshino J, Ubara Y, Wada T. Nonproteinuric diabetic kidney disease. Clin Exp Nephrol 2020, 24(7): 573-81. doi: 10.1007\/s10157-020-01881-0;","DOI":"10.1007\/s10157-020-01881-0"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wang C, Li C, Gong W, Lou T. New urinary biomarkers for diabetic kidney disease. Biomark Res 2013, 1(1): 9. doi: 10.1186\/2050-7771-1-9;","DOI":"10.1186\/2050-7771-1-9"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, Wang LN, Chen HC, Lai KN, Tan SY, Kim MJ. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal 2001, 15(4): 188-192. doi: 10.1002\/jcla.1026;","DOI":"10.1002\/jcla.1026"},{"key":"ref33","unstructured":"Hassan ME, Mahfouz MH, Shoman MS. Assessment of urinary type IV collagen, alpha-1 microglobulin, and transferrin in type 2 diabetes mellitus with nephropathy. J Med Sci Res 2020, 3(1): Article 4. doi: 10.4103\/JMSR.JMSR_74_19;"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Narita T, Hosoba M, Kakei M, Ito S. Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care 2006, 29(1): 142-4. doi: 10.2337\/diacare.29.1.142;","DOI":"10.2337\/diacare.29.01.06.dc05-1063"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Viswanathan V, Sivakumar S, Sekar V, Umapathy D, Kumpatla S. Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy. Indian J Nephrol 2015, 25(5): 269-73. doi: 10.4103\/0971-4065.145097;","DOI":"10.4103\/0971-4065.145097"},{"key":"ref36","unstructured":"Thi TND, Gia BN, Thi HLL, Thi TNC, Thanh HP. Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem 2020, 39(2): 224-30. doi: 10.2478\/jomb-2019-0037;"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Panduru NM, Forsblom C, Saraheimo M, Thorn L, Bierhaus A, Humpert PM, Groop PH; FinnDiane Study Group. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013, 36(7): 2077-83. doi: 10.2337\/dc12-1868;","DOI":"10.2337\/dc12-1868"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Urinarni biomarkeri u ranoj dijagnozi dijabetesne bolesti bubrega i dijabetesne retinopatije - pilot studija"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582605035T.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:42:42Z","timestamp":1779432162000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582605035T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-61991","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}